AGTC
Applied Genetic Technologies Corporation  |  NASDAQ
52wk high:19.86
52wk low:6.35
EPS:0.63
PE (ttm):13.89
Div Rate (ttm):-
Yield (ttm):-
Market Cap:$157.96M
Volume:
  • Dec. 16, 2016, 4:30 PM
    Dec. 16, 2016, 4:30 PM | 10 Comments
  • Dec. 13, 2016, 12:35 PM
    Dec. 13, 2016, 12:35 PM | 40 Comments
  • Nov. 9, 2016, 11:06 AM
    Nov. 9, 2016, 11:06 AM | 5 Comments
  • Nov. 8, 2016, 4:15 PM
    • Applied Genetic (NASDAQ:AGTC): Q3 EPS of $0.20 beats by $0.28.
    • Revenue of $11.8M (+6.7% Y/Y) beats by $1.59M.
    • Press Release
    Nov. 8, 2016, 4:15 PM
  • Sep. 28, 2016, 5:40 PM
    • Top gainers, as of 5.25 p.m.: AEGR +29.3%. PIR +7.5%. AGTC +5.5%. BBG +2.2%. HA +2.2%.
    • Top losers, as of 5.25p.m.: ITCI -67.7%. PRGS -9.9%. MT -6.2%. GWPH -4.9%.
    Sep. 28, 2016, 5:40 PM | 1 Comment
  • Sep. 16, 2016, 12:07 PM
    • C.R. Bard (NYSE:BCR) upgraded to Outperform from Market Perform by Wells Fargo.
    • DexCom (NASDAQ:DXCM) upgraded to Buy from Hold by Desjardins. Downgraded to Neutral from Buy with a $92 (1% downside risk) price target by BTIG Research.
    • Alimera Sciences (NASDAQ:ALIM) upgraded to Outperform from Market Perform by Cowen & Company.
    • Seattle Genetics (NASDAQ:SGEN) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $47 (13% downside risk) from $30.
    • Akorn (NASDAQ:AKRX) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $34 (19% upside) from $33.
    • Community Health Systems (NYSE:CYH) upgraded to Positive from Neutral by Susquehanna. Price target raised to $18 (66% upside).
    • AstraZeneca (NYSE:AZN) upgraded to Buy from Hold by Jefferies. Price target raised to GBX 5,800 (14% upside) from GBX 5,400. Downgraded to Neutral from Outperform with a GBX 5,200 (2% upside) price target by BNP Paribas.
    • McKesson (NYSE:MCK) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $189 (15% upside) from $210.
    • Cardinal Health (NYSE:CAH) downgraded to Neutral from Buy by Goldman Sachs. Price target lowered to $83 (8% upside) from $90.
    • Novavax (NASDAQ:NVAX) downgraded to Neutral from Outperform by Wedbush. Price target lowered to $2 (44% upside) from $14. Downgraded to Neutral from Buy by Citigroup. Price target lowered to $1.50 (8% upside) from $12. Downgraded to Neutral from Overweight by JPMorgan and Piper Jaffray.
    • Raptor Pharmaceutical (NASDAQ:RPTP) downgraded to Market Perform from Outperform by Cowen & Company.
    • Vitae Pharmaceuticals (NASDAQ:VTAE) downgraded to Market Perform from Outperform by BMO Capital.
    • Atara Biotherapeutics (NASDAQ:ATRA) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $16 (18% downside risk) from $23.
    • GlaxoSmithKline (NYSE:GSK) downgraded to Underperform from Neutral with a GBX 1,520 (6% downside risk) price target by BNP Paribas.
    • Applied Genetic Technologies (NASDAQ:AGTC) downgraded to Neutral from Buy by Roth Capital. Price target lowered to $12 (34% upside) from $34. Downgraded to Hold from Buy by Cantor Fitzgerald. Price target lowered to $15 (68% upside) from $32.
    • Cepheid (NASDAQ:CPHD) downgraded to Neutral from Outperform by Baird.
    Sep. 16, 2016, 12:07 PM | 8 Comments
  • Sep. 13, 2016, 12:45 PM
    Sep. 13, 2016, 12:45 PM | 6 Comments
  • Sep. 13, 2016, 11:15 AM
    Sep. 13, 2016, 11:15 AM
  • Sep. 13, 2016, 9:16 AM
    Sep. 13, 2016, 9:16 AM
  • Sep. 13, 2016, 8:59 AM
    • Thinly traded micro cap Applied Genetic Technologies (NASDAQ:AGTC) is down 29% premarket on light volume in response to its earnings announcement yesterday after the close.
    • Revenues for fiscal Q4 and fiscal 2016 were up nicely due to its collaboration with Biogen (NASDAQ:BIIB), but investors are hitting the sell button in response to its disclosure of slower-than-expected enrollment in the Phase 1/2 study of lead gene therapy candidate XLRS for the treatment of X-linked retinoschisis. The company says the delays stem from patients not meeting one or more eligibility criteria so it intends to expand the number of clinical trial sites. It also reports that mild-to-moderate ocular inflammation has been observed in most of the study participants which has been resolved by stopping treatment with XLRS or after treatment with topical or oral corticosteroids. AGTC has amended the study protocol to include the use of prophylactic corticosteroids which, in turn, required institutional review board approvals. This also contributed to the delay in patient recruitment. And, finally, there were apparently vendor errors that required the re-testing of the study drug for a process component. The product met all specifications but the company has established several backup vendors as well as internal testing capabilities to ensure uninterrupted supply.
    Sep. 13, 2016, 8:59 AM
  • Sep. 12, 2016, 5:39 PM
    Sep. 12, 2016, 5:39 PM | 7 Comments
  • Sep. 12, 2016, 4:28 PM
    • Applied Genetic (NASDAQ:AGTC): FQ4 EPS of $0.15 beats by $0.08.
    • Revenue of $12.1M (+1604.2% Y/Y) misses by $0.83M.
    • Shares -0.3%.
    • Press Release
    Sep. 12, 2016, 4:28 PM
  • May 9, 2016, 4:09 PM
    • Applied Genetic (NASDAQ:AGTC): Q1 EPS of $0.11 beats by $0.06.
    • Revenue of $12M (+4185.7% Y/Y) misses by $0.98M.
    May 9, 2016, 4:09 PM
  • Mar. 18, 2016, 11:38 AM
    • Applied Genetic Technologies (AGTC +0.8%) initiated with Buy rating with $25 (85% upside) price target by Janney Capital.
    • Nomura's Ed Ridley has been busy in devices. He rates the following companies a Buy: Boston Scientific (BSX +1%) PT: 22 (22% upside); Zimmer Biomet Holdings (ZBH +0.3%) PT: 123 (18% upside); Edwards Lifesciences (EW +0.8%) PT: 101 (19% upside); St. Jude Medical (STJ +0.5%) PT: 64 (19% upside); Stryker (SYK +0.7%) PT: 115 (6% upside); Medtronic (MDT +0.8%) PT: 86 (13% upside). He rates C.R. Bard (BCR +0.7%) Neutral with a PT of $205 (5% upside).
    • Tesaro (TSRO +2.6%) initiated with Buy rating and $65 (46% upside) price target by Citigroup.
    • CRH Medical (CRHM +0.1%) initiated with Buy rating and $5 (48% upside) price target by Canaccord Genuity.
    • Evoke Pharma (EVOK) initiated with an Outperform rating and $16 (258% upside) price target by Northland Securities.
    • NanoString Technologies (NSTG -0.2%) initiated with Buy rating and $21 (31% upside) price target by Janney Capital.
    • AbbVie (ABBV +0.6%) initiated with Hold rating and $63 (13% upside) price target by Deutsche Bank.
    Mar. 18, 2016, 11:38 AM | 5 Comments
  • Feb. 8, 2016, 4:14 PM
    • Applied Genetic (NASDAQ:AGTC): Q4 EPS of $0.17 beats by $0.36.
    • Revenue of $12.19M (+1775.4% Y/Y) beats by $3.43M.
    Feb. 8, 2016, 4:14 PM
  • Nov. 5, 2015, 4:42 PM
    • Applied Genetic (NASDAQ:AGTC): Q3 EPS of -$0.53 misses by $0.33.
    • Revenue of $11.1M (+1463.4% Y/Y) beats by $5.18M.
    Nov. 5, 2015, 4:42 PM